glp receptor 1 agonists Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Glucagon-like peptide 1 receptor agonists:

Several current labels carry boxed warnings related to thyroid C-cell tumors in rodents and strongly advise against use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

doi: 10.2337/diabetes.48.12.2270 [DOI] [PubMed] [Google Scholar] 130

That's our job as responsible scientists. It also remains unknown whether there will be any new side effects that pop up if people remain on these drugs for 30, 40, or 50-plus years

Comparative analysis of cancer risk among glucose-lowering agents Current clinical evidence indicates that various classes of antidiabetic drugs show substantial variability in their association with cancer risk

The science behind GLP-1 and immune function GLP-1 receptors are everywhere